Audited Supplier
BNP (B-type natriuretic peptide) is a cardiac biomarker primarily used to assess heart function and the severity of heart failure. It is released by cardiac cells, particularly in cardiac damage or heart failure cases, and helps regulate fluid balance and blood pressure by promoting sodium excretion and vasodilation.
In clinical practice, measuring BNP levels in the blood helps healthcare providers:
- Confirm the diagnosis of heart failure
- Assess the severity of heart failure
- Monitor treatment effectiveness and disease progression
BNP is often measured alongside its precursor molecule, NT-proBNP (N-terminal pro-B-type natriuretic peptide), both valuable in diagnosing and managing heart failure.
Linear
| Cal | Concentration | Result | AVERAGE |
| S1 | 0.11 | 0.10 | 0.11 |
| 0.10 | |||
| 0.12 | |||
| S2 | 0.53 | 0.53 | 0.52 |
| 0.46 | |||
| 0.58 | |||
| S3 | 2.17 | 1.96 | 2.14 |
| 2.28 | |||
| 2.17 | |||
| S4 | 10.1 | 9.28 | 10.64 |
| 12.04 | |||
| 10.59 | |||
| S5 | 27.57 | 26.27 | 26.88 |
| 27.66 | |||
| 26.70 | |||
| S6 | 39.32 | 41.69 | 42.73 |
| 44.67 | |||
| 41.82 |
Precision
| Cal | Concentration | Cal | Concentration | Cal | Concentration |
| R1 | 0.30 | R2 | 2.12 | R3 | 29.73 |
| 0.28 | 1.90 | 29.36 | |||
| 0.26 | 2.15 | 26.06 | |||
| 0.30 | 2.34 | 25.94 | |||
| 0.26 | 2.05 | 25.43 | |||
| 0.24 | 1.96 | 30.11 | |||
| 0.30 | 1.83 | 30.27 | |||
| 0.29 | 2.07 | 25.48 | |||
| 0.24 | 1.85 | 31.06 | |||
| 0.32 | 2.12 | 27.73 | |||
| AVE | 0.28 | AVE | 2.04 | AVE | 28.12 |
| SD | 0.03 | SD | 0.16 | SD | 2.23 |
| CV | 9.7% | CV | 7.7% | CV | 7.9% |
Method Comparison
- Main components:
| Name | Quantity | Unit |
| Test card with desiccant in a sealed foil pouch | 25 | tests |
| Sample diluent | 25 | bottles |
| ID chip | 1 | pcs |
| Instruction for use | 1 | pcs |
This test kit uses double antibody sandwich method principle and fluorescence immunochromatography analysis technology to quantitatively detect the concentration of BNP antigen in human plasma or whole blood samples.
This product is pre-embedded with fluorescent microspheres labeled mouse anti-BNP antibody and rabbit IgG antibody on the binding pad, and coated with mouse anti-BNP antibody and goat anti-rabbit IgG antibody respectively on the test line and control line of nitrocellulose membrane. When the sample is tested, the BNP antigen in the sample is combined with the fluorescent microspheres-labeled mouse anti-BNP antibody embedded on the conjugate pad to form the fluorescent microspheres-labeled mouse anti-BNP antibody-BNP immune complex. Under the action of chromatography, the immune complex flows along the nitrocellulose membrane to the end of the absorbent filter paper. On the test line, the immune complex is captured by the mouse BNP antibody pre-coated, forming the double-antibody sandwich structure of fluorescent microspheres labeled mouse anti-BNP antibody-BNP-mouse anti-BNP antibody and enriching. When the samples pass the control line, the rabbit IgG antibody labeled with fluorescent particles is enriched by combining with the pre-coated goat anti-rabbit IgG antibody. The concentration of BNP in the sample is positively correlated with the fluorescence intensity of the test line. The concentration of BNP in the sample is obtained through the test and analysis by the Immunofluorescence Analyzer.
Positive Result: Visible lines at both the control line (C) and the test line (T) on the test device indicate a positive result for BNP. This suggests the presence of elevated BNP concentration in the sample. Clinical correlation with other symptoms and tests is recommended for further evaluation.
Negative Result: Only the control line (C) is visible on the test device, with no line at the test region (T). This indicates a negative result for BNP, suggesting that BNP concentration was not detected in the sample. Clinical interpretation should consider additional diagnostic information.
Invalid Result: No visible colored band appears at the control line (C) on the test device. Possible reasons include insufficient sample volume, incorrect procedural technique, or use of expired test devices. It is advised to review the testing procedure and repeat with a new test device.
REFERENCE INTERVAL
- Normal reference interval: 0~ 100pg/mL.
INTERPRETATION OF TEST RESULTS
| Item name | Test results | Clinical application recommendations |
BNP | 0~ 100pg/mL | Normal level |
>100pg/mL | It indicates that the patient is at risk of congestive heart failure. |
Rapid test Kit-Colloidal gold | |||
Chlamydia | C. pneumoniae | H. Pylori | Malaria |
Rotavirus | Adenovirus | Rota/Adeno | Strep A |
Syphilis | HBsAg | HBsAb | HBsAg and HCV |
HBsAg /HCV /HIV /Syphilis | Dengue IgG/IgM | Dengue Ns1 | Dengue IgG/IgM /NS1 |
Chikungunya | Cholera | Typhoid | Tuberculosis |
HIV1+2 | HIV1+2 Ag/Ab | SEA | ToRCH |
HCV | HSV | RSV | TOXO |
Rubella | CMV | Norovirus | Leishmania |
Filariasis | Leptospira | Monkeypox | M.Pneumoniae |
Chagas | Brucella | HPV | |
Influenza A+B | Influenza A+B | Influenza A+B/RSV | FOB |
AMH | AMH/FSH | MxA | cTnI |
| HCG | LH | 25-OH VD | |
| The Customized cut -off and sizes are available | |||
| Lateral Flow Quantitive Test Kit | |||
Class | Rapid Test | Sample type | Detection Range |
Cardiac Marker | cTn I | Serum/Plasma/Whole blood | 0.1~40 ng/mL |
NT-proBNP | Serum/Plasma/Whole blood | 100~20000 pg/mL | |
CK-MB | Serum/Plasma/Whole blood | 1ng/mL~100ng/mL | |
BNP | Plasma/Whole blood | 5pg/mL~5000pg/mL | |
cTnT | Serum/Plasma/Whole blood | 30pg/mL~25000pg/mL | |
Myo | Serum/Plasma/Whole blood | 5ng/mL~500ng/mL | |
cTnl/ Myo/ CK-MB | Serum/Plasma/Whole blood | cTnI: 0.1ng/mL~40ng/mL;Myo: 5ng/mL~500ng/mL;CK-MB: 1ng/mL~100ng/mL | |
D-Dimer/ cTnI/ NT-proBNP | Serum/Plasma/Whole blood | Dimer: 0.1mg/L~10mg/L; cTnI: 0.1ng/mL~40ng/mL; NT-proBNP: 100pg/mL~20000pg/mL | |
Inflammatory | PCT | Serum/Plasma/Whole blood | 0.1~100 pg/mL |
CRP | Serum/Plasma/Whole blood | 0.5~200mg/L | |
SAA | Serum/Plasma/Whole blood | 5~300mg/L | |
IL-6 | Serum/Plasma/Whole blood | 5~5000 pg/mL | |
PCT/ IL-6 | Serum/Plasma/Whole blood | PCT: 0.1ng/mL~100ng/mL;IL-6:10pg/mL~10000pg/mL | |
CRP/ SAA | Serum/Plasma/Whole blood | CRP 0.5mg/L~200mg/L;SAA 5mg/L~300mg/L, | |
Glycated hemoglobin | HbA1c | Whole blood | 3~14% |
Tumor | PSA | Serum/Plasma/Whole blood | 2~80 ng/mL |
HCG | HCG | Serum/Plasma/Whole blood | 5~200000mIU/mL |
Anticoagulation | D-Dimer | Plasma/Whole blood | 0.1~10 mg/L |
Endocrine | TSH | Serum/Plasma/Whole blood | 0.1mIU/L ~100.0mIU/L |
T3 | Serum/Plasma/Whole blood | 0.61~9.22 nmol/L | |
T4 | Serum/Plasma/Whole blood | 12.87~310 nmol/L | |
FT3 | Serum/Plasma/Whole blood | 0.60pmol/L ~45.00pmol/L | |
FT4 | Serum/Plasma/Whole blood | 1.00pmol/L ~100.00pmol/L | |
AMH | Serum/Plasma/Whole blood | 0.1~16 ng/mL | |
PROG | Serum/Plasma | 0.35ng/mL~60ng/mL | |
PRL | Serum/Plasma/Whole blood | 1 ng/mL~200ng/mL | |
FSH | Serum/Plasma/Whole blood | 1mIU/mL~100 mIU/mL | |
LH | Serum/Plasma/Whole blood | 1 ~100 mIU/mL | |
TES | Serum/Plasma | 0.2~15 ng/mL | |
E2 | Serum/Plasma/Whole blood | 15 pg/mL~3000pg/mL | |
Bone | 25-OH-VD | Serum/Plasma/Whole blood | 5.0ng/mL~100.0ng/mL |
| The Customized cut -off and size are available | |||
